MedPath

Observational Study of Blinatumomab

Completed
Conditions
Blincyto Use in Routine Clinical Practice
Registration Number
NCT03117621
Lead Sponsor
Amgen
Brief Summary

An observational study of blinatumomab safety and effectiveness, utilisation, and treatment practices.

Detailed Description

The primary objective of this study is to characterize the safety of Blincyto in routine clinical practice. Blincyto effectiveness, medication errors, and utilisation; and select healthcare resource use while using Blincyto will also be described. Safety and effectiveness of Blincyto in specified subgroups of patients will also be assessed.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
279
Inclusion Criteria
  • Medical records of patients initiating Blincyto after country-specific reimbursement in routine clinical practice will be eligible for extraction.
Exclusion Criteria
  • Medical records of patients who have participated in Blincyto clinical trials will be excluded since their treatment will be prescribed by the study protocol unless the patient is receiving new Blincyto treatment outside the clinical trial.
  • Medical records of patients participating in other Amgen non-interventional prospective studies in which safety endpoints are collected will be excluded.
  • Medical records of patients who have received Blincyto via an expanded access/compassionate use program will be excluded.
  • In countries where patient informed consent is required for access to their medical records, any patient who does not provide informed consent will be excluded.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of Blincyto administrations with medication errorsEstimated to be 100 days

Proportion of Blincyto administrations with medication errors, defined as an unintended failure in the drug treatment process that leads to, or has the potential to lead to, harm to the patient, identified through medical records. Types of medication errors will also be described

* incorrect Blincyto dose administered/prepared (eg. drug concentration, device issues, treatment according to SmPC)

* does not include treatment related to dexamethasone.

Proportion of patients with specified AEs as mentioned in descriptionEstimated to be 100 days

* Neurological adverse events

* Opportunistic infections

* Cytokine release syndrome

Time to onset of first specified AEsEstimated to be 100 days

Time to onset of first specified AEs.

Summary of duration of specified AEs as detailed in the description (all events and resolved/recovered events)Estimated to be 100 days

Summary of duration of specified AEs (all events and resolved/recovered events)

* Neurological adverse events

* Opportunistic Infections

Secondary Outcome Measures
NameTimeMethod
Proportion of patients receiving allogeneic HSCT amongst patient sub-groupsEstimated to be 100 days

Proportion of patients receiving allogeneic HSCT amongst patient sub-groups. Defined for the subset of subjects who achieved CR.

Blincyto utilisation: Number of cycles initiatedEstimated to be 100 days
Disease Free Survival (DFS) timeEstimated to be 100 days

Disease Free Survival time - Defined as time from initiation of Blincyto (for MRD positive patients at initiation) until date of relapse or death.

Blincyto utilisation: Number of bag changesEstimated to be 100 days
Blincyto utilisation: Proportion of patients with treatment changesEstimated to be 100 days

Treatment changes include interruption, discontinuation, and dose reduction.

Select healthcare resource use: Proportion of treatment days that were inpatientEstimated to be 100 days
Select healthcare resource use: Incidence of hospitalization not related to infusionEstimated to be 100 days
Proportion of patients with AEs as detailed in the descriptionEstimated to be 100 days

Incidence of all AEs collected in this study (overall, and by severity and seriousness) occurring during blinatumomab treatment and up to 30 days after completion of treatment

• Incidence of specified AEs and all AEs collected in this study among patient subgroups defined by demographic and clinical factors.

Proportion of patients achieving CR/CRh*/CRi amongst patient sub-groupsEstimated to be 100 days

Proportion of patients achieving CR/CRh\*/CRi within 2 cycles Blincyto treatment

* CR defined as ≤ 5% bone marrow blasts, platelets more than 100,000 cells per µL, and absolute neutrophil count \> 1,000 cells per µL

* CRh\* defined as ≤ 5% bone marrow blasts, platelets more than 50,000 cells per µL, and absolute neutrophil count \> 500 cells per µL

* CRi defined as ≤ 5% bone marrow blasts and incomplete recovery of peripheral blood counts.

Overall survival (OS) time amongst patient sub-groupsEstimated to be 100 days

Overall survival (OS) time - defined as time from initiation of Blincyto until death.

Proportion of patients with MRD achieving CR/CRh*/CRi within 2 cycles of BlincytoEstimated to be 100 days

Overall and amongst patient sub-groups - Proportion of patients with minimal residual disease (MRD) among those who achieve CR/CRh\*/CRi within two cycles of Blincyto treatment - hematologic MRD detected by polymerase chain reaction (PCR) (or flow cytometry) at a level of

1 x 10-4 or higher.

Blincyto utilisation: Number of completed cyclesEstimated to be 100 days
Select healthcare resource use: Total number of days of inpatient Blincyto treatmentEstimated to be 100 days
Select healthcare resource use: Number of bag changes in each settingEstimated to be 100 days

Setting of blincyto bag changes include in the hospital, in the outpatient clinic, or at home.

Proportion of patients achieving Complete Remission overall and amongst patient sub-groupsEstimated to be 100 days

* Proportion of patients achieving Complete Remission within 2 cycles of Blincyto treatment

* Complete remission - Defined as ≤ 5% bone marrow myeloblasts, platelets more than 100,000 cells per µL, and absolute neutrophil count \> 1,000 cells per µL.

1-year and 100-day mortality proportion after allogeneic HSCT amongst patient sub-groupsEstimated to be 100 days

1-year and 100-day mortality proportion after allogeneic HSCT amongst patient sub-groups. Defined for the subset of subjects who achieved CR.

Relapse-free survival (RFS) time amongst patient sub-groupsEstimated to be 100 days

Relapse-free survival (RFS) time - defined as time from CR/CRh\*/CRi until relapse (proportion of blasts in bone marrow \> 5% or blasts in peripheral blood after documented CR/CRh\*/CRi) or death. Defined for the subset of subjects who achieved CR.

Blincyto utilisation: Total number of days of administrationEstimated to be 100 days
Blincyto utilisation: Proportion of patients with dose step-up on Day 8Day 8
Select healthcare resource use: Length of hospital stay not related to infusionEstimated to be 100 days

Trial Locations

Locations (80)

Ordensklinikum Linz Elisabethinen

🇦🇹

Linz, Austria

Landeskrankenhaus Salzburg

🇦🇹

Salzburg, Austria

Hanuschkrankenhaus

🇦🇹

Wien, Austria

Fakultni nemocnice Hradec Kralove

🇨🇿

Hradec Kralove, Czechia

Fakultni nemocnice Plzen

🇨🇿

Plzen, Czechia

Ustav hematologie a krevni transfuze

🇨🇿

Praha 2, Czechia

Helsinki University Central Hospital

🇫🇮

Helsinki, Finland

Centre Hospitalier Universitaire Dieu Angers

🇫🇷

Angers cedex 09, France

Centre Hospitalier Regional Universitaire de Besancon, Hopital Jean Minjoz

🇫🇷

Besançon, France

Hopital d Instruction des Armee

🇫🇷

Clamart, France

Scroll for more (70 remaining)
Ordensklinikum Linz Elisabethinen
🇦🇹Linz, Austria

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.